| Published Application/Species/Sample/Dilution | Reference |
|---|
- other; human; loading ...; fig 4c
| Ng P, Li J, Jeong K, Shao S, Chen H, Tsang Y, et al. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 2018;33:450-462.e10 pubmed publisher |
- reverse phase protein lysate microarray; human; loading ...; fig st6
| Cherniack A, Shen H, Walter V, Stewart C, Murray B, Bowlby R, et al. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell. 2017;31:411-423 pubmed publisher |
- western blot; rat; 1:1000; loading ...; fig 5c
| Heffernan C, Jain M, Liu T, Kim H, Barretto K, Li H, et al. Nectin-like 4 Complexes with Choline Transporter-like Protein-1 and Regulates Schwann Cell Choline Homeostasis and Lipid Biogenesis in Vitro. J Biol Chem. 2017;292:4484-4498 pubmed publisher |
- reverse phase protein lysate microarray; human; loading ...; fig 3a
| . Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378-384 pubmed publisher |
- western blot; human; loading ...; fig 6a, 6d
| Buta C, Benabou E, Lequoy M, Régnault H, Wendum D, Meratbene F, et al. Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin. J Exp Clin Cancer Res. 2016;35:126 pubmed publisher |
- western blot; human; 1:1000; loading ...; fig 3
| Alver T, Lavelle T, Longva A, Øy G, Hovig E, Bøe S. MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma. Oncotarget. 2016;7:55128-55140 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:50; fig 1g
| Lattanzio R, Veschi S, Aceto G, Curia M, Cama A, De Lellis L, et al. Overexpression of PY1289-HER3 in sporadic pulmonary carcinoid from patients bearing MEN1 gene variants. Oncol Lett. 2016;12:453-458 pubmed |
- immunohistochemistry - paraffin section; mouse; fig 6
| Mancini M, Lien E, Toker A. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis. Oncotarget. 2016;7:17301-13 pubmed publisher |
- western blot; human; fig 1
| Meng Y, Zheng L, Yang Y, Wang H, Dong J, Wang C, et al. A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors. Oncogenesis. 2016;5:e211 pubmed publisher |
- western blot; human; fig 3e
| Stindt S, Cebula P, Albrecht U, Keitel V, Schulte Am Esch J, Knoefel W, et al. Hepatitis C Virus Activates a Neuregulin-Driven Circuit to Modify Surface Expression of Growth Factor Receptors of the ErbB Family. PLoS ONE. 2016;11:e0148711 pubmed publisher |
- western blot; human; fig 1
| Cao K, Gong H, Qiu Z, Wen Q, Zhang B, Tang T, et al. Hepatitis B virus X protein reduces the stability of Nrdp1 to up-regulate ErbB3 in hepatocellular carcinoma cells. Tumour Biol. 2016;37:10375-82 pubmed publisher |
- western blot; human; fig 1
| Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam K, et al. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS ONE. 2016;11:e0147344 pubmed publisher |
- immunocytochemistry; human; fig s3
- western blot; human; fig 1
| Jeong J, VanHouten J, Dann P, Kim W, Sullivan C, Yu H, et al. PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer. Proc Natl Acad Sci U S A. 2016;113:E282-90 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100
| Creedon H, Balderstone L, Muir M, Balla J, Gómez Cuadrado L, Tracey N, et al. Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer. Dis Model Mech. 2016;9:131-40 pubmed publisher |
- western blot; human; loading ...; fig 1
| Huguet F, Fernet M, Giocanti N, Favaudon V, Larsen A. Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status. Target Oncol. 2016;11:371-81 pubmed publisher |
- western blot; human; loading ...; fig 3a
| Chen J, Chen Y, Yen C, Chen W, Huang W. HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. Oncotarget. 2016;7:473-89 pubmed publisher |
- western blot; human; fig 2
| Safavi S, Järnum S, Vannas C, Udhane S, Jonasson E, Tomić T, et al. HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo. Oncotarget. 2016;7:433-45 pubmed publisher |
- western blot; human; 1:200; fig 1
| Blancafort A, Giró Perafita A, Oliveras G, Palomeras S, Turrado C, Campuzano Ã, et al. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs. PLoS ONE. 2015;10:e0131241 pubmed publisher |
- western blot; human; fig 2
| Hutchinson K, Johnson D, Johnson A, Sanchez V, Kuba M, Lu P, et al. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget. 2015;6:22348-60 pubmed |
| Rios Doria J, Sabol D, Chesebrough J, Stewart D, Xu L, Tammali R, et al. A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways. Mol Cancer Ther. 2015;14:1637-49 pubmed publisher |
- immunohistochemistry - paraffin section; mouse; loading ...; fig 5b
- western blot; mouse; loading ...; fig 1c
| Meneses Lorente G, Friess T, Kolm I, Hölzlwimmer G, Bader S, Meille C, et al. Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody. Cancer Chemother Pharmacol. 2015;75:837-50 pubmed publisher |
- western blot; human; fig 2
| Momeny M, Saunus J, Marturana F, McCart Reed A, Black D, Sala G, et al. Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget. 2015;6:3932-46 pubmed |
- western blot; human; fig 3
| Blair B, Wu X, Zahari M, Mohseni M, Cidado J, Wong H, et al. A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations. Proteomics. 2015;15:318-26 pubmed publisher |
| Wang J, Mikse O, Liao R, Li Y, Tan L, Jänne P, et al. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 2015;34:2167-77 pubmed publisher |
- immunohistochemistry; human; 1:30
| Cha Y, Han S, Seol H, Oh D, Im S, Bang Y, et al. Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. Anticancer Res. 2014;34:4275-80 pubmed |
| Kugel C, Hartsough E, Davies M, Setiady Y, Aplin A. Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor. Cancer Res. 2014;74:4122-32 pubmed publisher |
- western blot; human; fig 1c
| Zhang L, Castanaro C, Luan B, Yang K, Fan L, Fairhurst J, et al. ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models. Mol Cancer Ther. 2014;13:1345-55 pubmed publisher |
- western blot; human; fig 3
| Ni M, Chen Y, Fei T, Li D, Lim E, Liu X, et al. Amplitude modulation of androgen signaling by c-MYC. Genes Dev. 2013;27:734-48 pubmed publisher |
| Lindberg K, Helguero L, Omoto Y, Gustafsson J, Haldosén L. Estrogen receptor ? represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Breast Cancer Res. 2011;13:R43 pubmed publisher |
| Piulats J, Kondo J, Endo H, Ono H, Hagihara T, Okuyama H, et al. Promotion of malignant phenotype after disruption of the three-dimensional structure of cultured spheroids from colorectal cancer. Oncotarget. 2018;9:15968-15983 pubmed publisher |
| Kitowska K, Kowalska A, Mieszkowska M, Piasecka D, Skladanowski A, Romanska H, et al. Progesterone impairs Herceptin effect on breast cancer cells. Oncol Lett. 2018;15:1817-1822 pubmed publisher |
| Fowler D, Stewart S, Seredick S, Eisen J, Stankunas K, Washbourne P. A MultiSite Gateway Toolkit for Rapid Cloning of Vertebrate Expression Constructs with Diverse Research Applications. PLoS ONE. 2016;11:e0159277 pubmed publisher |
| Baumann J, Wong J, Sun Y, Conklin D. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells. BMC Cancer. 2016;16:551 pubmed publisher |
| Turpin J, Ling C, Crosby E, Hartman Z, Simond A, Chodosh L, et al. The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment. Oncogene. 2016;35:6053-6064 pubmed publisher |
| Takagi S, Banno H, Hayashi A, Tamura T, Ishikawa T, Ohta Y. HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285. Oncoscience. 2014;1:196-204 pubmed |
| Greenfield E, Griner E. Registered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors. elife. 2014;3: pubmed publisher |
| Wang G, Zhao X, Meng Z, Kern M, Dietrich A, Chen Z, et al. The brown fat-enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis. Nat Med. 2014;20:1436-1443 pubmed publisher |
| D Souza J, Reddy S, Goldsmith L, Shchaveleva I, Marks J, Litwin S, et al. Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies. PLoS ONE. 2014;9:e112376 pubmed publisher |
| Xiao Z, Sperl B, Ullrich A, Knyazev P. Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status. Oncotarget. 2014;5:12877-90 pubmed |
| Xie T, Lim S, Westover K, Dodge M, Ercan D, Ficarro S, et al. Pharmacological targeting of the pseudokinase Her3. Nat Chem Biol. 2014;10:1006-12 pubmed publisher |
| Zhang K, Jones L, Lim S, Maher C, Adkins D, Lewis J, et al. Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC. Oncotarget. 2014;5:9281-94 pubmed |
| Mu Z, Klinowska T, Dong X, Foster E, Womack C, Fernandez S, et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models. J Exp Clin Cancer Res. 2014;33:47 pubmed publisher |
| Färkkilä A, Andersson N, Butzow R, Leminen A, Heikinheimo M, Anttonen M, et al. HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor-a long-term follow-up study. Cancer Med. 2014;3:526-36 pubmed publisher |
| Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H, et al. Prevalence, clinicopathologic characteristics, and molecular associations of EGFR exon 20 insertion mutations in East Asian patients with lung adenocarcinoma. Ann Surg Oncol. 2014;21 Suppl 4:S490-6 pubmed publisher |
| Paulson A, Linklater E, Berghuis B, App C, Oostendorp L, Paulson J, et al. MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance. Mol Cancer Res. 2013;11:1112-21 pubmed publisher |
| Sak M, Szymanska M, Bertelsen V, Hasmann M, Madshus I, Stang E. Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3. Carcinogenesis. 2013;34:2031-8 pubmed publisher |
| Scheer J, Sandoval W, Elliott J, Shao L, Luis E, Lewin Koh S, et al. Reorienting the Fab domains of trastuzumab results in potent HER2 activators. PLoS ONE. 2012;7:e51817 pubmed publisher |
| Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, et al. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther. 2012;11:2149-57 pubmed publisher |
| Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev I, et al. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Am J Pathol. 2012;181:1034-43 pubmed publisher |
| Deharvengt S, Marmarelis M, Korc M. Concomitant targeting of EGF receptor, TGF-beta and SRC points to a novel therapeutic approach in pancreatic cancer. PLoS ONE. 2012;7:e39684 pubmed publisher |
| Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, et al. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res. 2012;18:3592-602 pubmed publisher |
| Wong V, Stange D, Page M, Buczacki S, Wabik A, Itami S, et al. Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. Nat Cell Biol. 2012;14:401-8 pubmed publisher |
| Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, et al. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res. 2012;18:1663-71 pubmed publisher |
| Berg D, Wolff C, Langer R, Schuster T, Feith M, Slotta Huspenina J, et al. Discovery of new molecular subtypes in oesophageal adenocarcinoma. PLoS ONE. 2011;6:e23985 pubmed publisher |
| Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y, et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs. 2012;30:1352-60 pubmed publisher |
| Jay S, Kurtagic E, Alvarez L, de Picciotto S, Sanchez E, Hawkins J, et al. Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes. J Biol Chem. 2011;286:27729-40 pubmed publisher |
| Zhang Y, Qu Z, Kim S, Shi V, Liao B, Kraft P, et al. Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection. Gene Ther. 2011;18:326-33 pubmed publisher |
| Weigelt B, Lo A, Park C, Gray J, Bissell M. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat. 2010;122:35-43 pubmed publisher |
| Frogne T, Laenkholm A, Lyng M, Henriksen K, Lykkesfeldt A. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res. 2009;11:R11 pubmed publisher |
| Sergina N, Rausch M, Wang D, Blair J, Hann B, Shokat K, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445:437-41 pubmed |
